Dr. Yardley on Emerging Agents in HER2-Positive Breast Cancer

Denise A. Yardley, MD
Published: Thursday, Sep 15, 2016



Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses some of the emerging agents in HER2-positive breast cancer.

One promising therapy is ONT-380 (tucatinib), which is currently under investigation in three phase I studies in combination with other anti-HER2 therapies. ONT-380 is similar to lapatinib (Tykerb), though the latter is fraught with several toxicities, says Yardley.

So far, ONT-380 has demonstrated good penetrance into the CNS, and patients treated with the agent have been stable, asymptomatic, and are generally tolerating the drug well in combination with trastuzumab (Herceptin).


Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses some of the emerging agents in HER2-positive breast cancer.

One promising therapy is ONT-380 (tucatinib), which is currently under investigation in three phase I studies in combination with other anti-HER2 therapies. ONT-380 is similar to lapatinib (Tykerb), though the latter is fraught with several toxicities, says Yardley.

So far, ONT-380 has demonstrated good penetrance into the CNS, and patients treated with the agent have been stable, asymptomatic, and are generally tolerating the drug well in combination with trastuzumab (Herceptin).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x